In short. Sun protection, retinoids and devices each carry defined indications, and nothing is approved as a treatment for ageing itself. The gap between them.
Key points
- Sun protection does slow photoageing, and that follows from what it does rather than from an approval for slowing anything.
- Reducing exposure reduces accumulation.
- It is the only intervention in the category whose benefit is a direct consequence of its approved function, and it is the one least likely to be described as a longevity product.
Approvals in this field are narrow and specific, and the word longevity belongs to none of them. The distance between what is approved and what is claimed is where most of the marketing in this category lives.
Three kinds of approval, three meanings
A sunscreen is regulated for the protection it provides against ultraviolet radiation. A topical retinoid is approved for defined skin conditions and, in some markets, for fine lines. A device is approved for an endpoint such as wrinkle reduction or pigment, and the approval belongs to the device and the indication rather than to the family it sits in. Each of those is checkable and each describes something much narrower than the claim usually built on top of it.
The gap, and why it is so large here
The gap is larger in this subject than in most, because the claim being made is about a rate rather than about a finding. No product is approved to change the rate at which skin ages, and the studies that would support such an approval — years of follow-up against a control, with an appearance graded consistently — have not been run for the supplements, the drinks or the programmes sold under the name.
The one exception works by a different route
Sun protection does slow photoageing, and that follows from what it does rather than from an approval for slowing anything. Reducing exposure reduces accumulation. It is the only intervention in the category whose benefit is a direct consequence of its approved function, and it is the one least likely to be described as a longevity product.
What to check
A page making a longevity claim can be checked in one step: name the product, and ask what it is approved for. If the answer is a sunscreen, the claim is coherent and the benefit follows from the protection. If the answer is a product approved for something unrelated, or approved for nothing of the kind, the claim has been built on a category word rather than on an indication. That check takes a moment and it resolves most of what the category contains.
Approval claims that do not hold
- An approval for protection described as an approval for slowing ageing.
- A product approved in one market described as approved everywhere.
- A laboratory finding described as though it were the basis of an approval.
Reported separately, approval and evidence are both useful. Merged into a single sentence about longevity, they are neither.
Frequently asked questions
Is anything approved as a treatment for skin ageing?
No. Approvals in this field are for defined indications on defined products: protection against ultraviolet radiation for a sunscreen, defined skin conditions and in some markets fine lines for a topical retinoid, and endpoints such as pigment, texture or wrinkles for a device. Nothing is approved for ageing itself.
Does a sunscreen need an approval to slow photoageing?
Its benefit follows from what it does rather than from an approval for longevity. A sunscreen is regulated for the protection it provides, and it is the reduction in exposure that limits further photodamage. That is why the strongest evidence in the field belongs to a product that is not marketed as a longevity treatment at all.
Why does the difference between approvals matter?
Because three products with completely different approvals can all be described with the same word. A sunscreen, a supplement and a device can each be called a longevity product while only two of them are approved for anything relevant, and the approvals they carry are narrower than the sentences around them.
Risks & Limitations
- Sun protection has the strongest evidence in the field and almost no downside; almost nothing else in the category does.
- Nothing is approved as a treatment for skin ageing itself, and approvals belong to products and defined endpoints.
- Topical retinoids irritate and require continued use; devices carry burn, pigment change and scarring.
- Supplements, drinks and programmes sold as longevity have no demonstrated effect on how skin ages in people.
- A mechanism is a reason to study something rather than a result, and a treated finding can recur.
When to Seek Care
- A mole or patch that is changing in size, shape or colour — have it assessed by a clinician.
- A lesion that bleeds, itches or will not heal — have it assessed by a clinician.
- Blistering, crusting or pigment change that follows a device treatment — have it assessed by a clinician.
- A rash, or irritation from a topical that does not settle when use is paused, is assessed by a clinician rather than managed indefinitely.
References & Further Reading
- World Health Organization (WHO) — ultraviolet radiation and skin cancer prevention guidance
- U.S. Food and Drug Administration (FDA) — sunscreen and topical product labelling and indications
- National Medical Products Administration (NMPA, China) — approved products and their indications
- Cochrane Library — systematic reviews of topical treatments and photoprotection
- Chinese Medical Association Dermatology Branch — clinical guidance
This page is a review of published evidence and regulation, not medical advice, and it does not cite individual studies. It is not a booking page and it does not recommend a product or treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.